Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tinlarebant · LBS-008, BPN-14967

Small molecule · developed by Belite Bio

Phase 3 Most advanced trial
BLTE Developer
4 Registered trials

What is Tinlarebant?

Tinlarebant (LBS-008, BPN-14967) is an orally administered tablet studied in healthy volunteers and in dry age-related macular degeneration, including geographic atrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LBS-008, BPN-14967
Drug type
Small molecule
Therapy area
Ophthalmology
Developer
Belite Bio, Inc (BLTE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
63WI9S8P1M

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05949593 Phase 3 Geographic Atrophy Active not recruiting BLTE
NCT05667688 Phase 1 Healthy Volunteer Completed BLTE
NCT04005807 Phase 1 Healthy Volunteers Completed BLTE
NCT03735810 Phase 1 Healthy Volunteer Completed BLTE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Geographic AtrophyDry Age-related Macular DegenerationHealthy Volunteer

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BLTE page.

Follow BLTE, the company behind Tinlarebant

See BLTE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BLTE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.